What are the injection sites for skyrizi?

Where should Skyrizi injections go for psoriasis?

Skyrizi (risankizumab) comes in a prefilled syringe or pen and is meant for subcutaneous use only. The approved injection sites are the front of the thighs, the abdomen (at least two inches from the navel), and the upper outer arms when another person gives the shot. Rotate the site each time and avoid skin that is tender, bruised, red, or hard.

What happens if you inject Skyrizi into the wrong place?

Injecting into muscle or a vein instead of fat tissue can change how the drug is absorbed and may increase local reactions. If the needle goes too shallow or hits scar tissue, the dose may not be delivered fully. Patients should call their doctor or pharmacist if they suspect an incorrect injection.

Can you give Skyrizi shots at home?

Yes. After proper training, most adults self-inject in the thigh or stomach. A caregiver can use the upper arm site. The pen or syringe should be removed from the refrigerator 30–60 minutes before use so it reaches room temperature and reduces stinging.

How often is Skyrizi injected for psoriasis or psoriatic arthritis?

After two starter doses at weeks 0 and 4, maintenance dosing is every 12 weeks. Missing a dose by more than a couple of weeks may reduce how well the drug works; patients should resume on the next scheduled date rather than doubling up.

What side effects are patients reporting at the injection site?

Mild redness, itching, or swelling at the site is common and usually fades within a day or two. Serious injection-site reactions are rare but can include intense swelling or signs of infection. Any reaction that worsens or spreads should be checked by a healthcare provider.

How does Skyrizi injection compare with other IL-23 inhibitors?

Skyrizi uses a 12-week schedule after loading, while guselkumab (Tremfya) and tildrakizumab (Ilumya) also allow self-injection but differ in starter dosing and sometimes in volume per shot. Choice often comes down to insurance coverage, patient preference for dosing frequency, and individual response.

When does the Skyrizi patent expire?

The composition-of-matter patent for risankizumab is listed to expire in 2033 in the United States, although additional formulation or method patents could extend protection. DrugPatentWatch.com tracks these dates and related litigation.